News
GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month
Starting today, eligible patients can use GoodRx to self-pay for Ozempic ® and Wegovy ® pens for $499-per-month at over 70,000 retail pharmacies nationwide. To learn more, visit: GoodRx.com/Ozempic or GoodRx.com/Wegovy
GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX ...
GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...
GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies ...
Goodrx Holdings Inc (NASDAQ: GDRX) closed roughly 50% higher on August 18 after Bagsværd-headquartered Novo Nordisk (NYSE: ...
StockStory.org on MSN2d
Why GoodRx (GDRX) Stock Is Trading Up Today
Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...
We recently published 12 Best Healthcare Stocks to Buy Under $30. GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the best ...
One stock to keep an eye on is GoodRx (GDRX). GDRX is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. The stock has a Forward P/E ratio of 10.11.
Read More on GDRX: GoodRx sees FY24 revenue at ‘low end’ of $800M-$810M, consensus $806.38M GoodRx sees Q3 revenue $193M-$197M, consensus $202.37M GoodRx reports Q2 adjusted EPS 8c, consensus 9c ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback